JRJoanna Rymuza

Joanna Rymuza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanna Rymuza has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Dorota Białas-Niedziela

    Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland

    2 shared publications
  • Monika Turczyńska

    Ophthalmology Outpatient Clinic, University Clinical Center, Medical University of Warsaw, Warsaw, Poland

    2 shared publications
  • Piotr Miśkiewicz

    Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland

    2 shared publications
  • Aleksander Kuś

    Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland

    1 shared publication
  • Aleksander Kuś

    Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland

    1 shared publication
  • Biljana Nedeljković Beleslin

    Clinic of Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center of Serbia, Belgrade, Serbia

    1 shared publication

Latest Publications

  • Tocilizumab in Active, Moderate-to-Severe, Glucocorticoid-Resistant Thyroid Eye Disease: An Open-Label Prospective Study in Two Independent Cohorts

    by Joanna Rymuza, Aleksander Kuś, Biljana Nedeljković Beleslin, Miroslav Knežević, Dorota Białas-Niedziela, Monika Turczyńska, Mirjana Stojković, Bojan Marković, Dariusz KęCik, Miloš Žarković, et al.

    Background: Treatment of active, moderate-to-severe thyroid eye disease (TED) remains a challenge. Up to 55% of patients show an incomplete response to intravenous (IV) glucocorticoids (GCs), and relapses are common. Tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, has been proposed as a second-line therapy for GC-resistant TED. Methods: We performed an open-label, prospective study at two tertiary TED referral centers (Warsaw, Poland; Belgrade, Serbia) from May 2022 to May 2025. Adults with active, moderate-to-severe, GC-resistant TED received TCZ 8 mg/kg IV every 4 weeks for four cycles and were followed for 24 weeks. Primary endpoints were (1) improvement in the composite ophthalmic score and (2) improvement in disease-specific quality of life (Graves’ ophthalmopathy quality of life questionnaire [GO-QoL]). Secondary endpoints included changes in clinical activity score (CAS), proptosis, eyelid aperture, diplopia, thyrotropin receptor antibody (TRAb) levels, and safety. The trial was registered at ClinicalTrials.gov (NCT06367517). Results: A total of 44 patients underwent TCZ treatment (Warsaw, n = 32; Belgrade, n = 12). Both primary endpoints were met by 20/32 (62.5%) patients at Warsaw and all 12/12 (100%) patients at Belgrade. CAS reduction by ≥2 points was observed in 24/32 (75%) and 12/12 (100%) patients, respectively. A reduction of ≥2 mm in proptosis occurred in 19/32 (59.4%) and 7/12 (58.3%). Diplopia improved by ≥1 grade in Gorman score in 7/32 (21.9%) and 6/12 (50%). Eyelid aperture decreased by ≥2 mm in 11/32 (34.4%) and 8/12 (66.7%). Median TRAb levels decreased from 7.0 to 2.1 IU/L (Warsaw) and from 4.7 to 2.0 IU/L (Belgrade). No patients experienced TED deterioration. Adverse events occurred in 18/44 (40.9%) patients (47 events, only 1 severe). Conclusions: In this prospective, real-world study conducted in two independent cohorts of patients with GC-resistant, active, moderate-to-severe TED, TCZ was associated with clinically meaningful improvements in composite ophthalmic score response, CAS, proptosis, and quality of life, with a generally acceptable safety profile. These findings support TCZ as an effective and safe second-line therapeutic option for GC-resistant TED.


  • Open Access

    Predictive value of thyroid-related biomarkers in Graves’ disease – a systematic review

    by Zofia Marek, Szymon Ejzak, Julia Wiktorowska, Magdalena Lesisz, Katsiaryna Palitsyna, Michał Szabelski, Joanna Rymuza

    Graves’ disease is the most common cause of hyperthyroidism and is characterized by a clinical course often difficult to predict. While some patients experience relapses, others achieve long-term remission. It is crucial to improve the accuracy of predicting disease course in order to identify patients who are most likely to benefit from antithyroid drug therapy, thereby avoiding potential complications associated with more radical treatments. The aim of this systematic review is to gather up-to-date knowledge in this field and, based on it, to determine whether commonly available thyroid-related biomarkers can predict the likelihood of remission after antithyroid drug therapy. Thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and TSH-receptor antibodies (TRAb) were evaluated. A total of 964 articles (394 from PubMed and 570 from Embase) were initially identified. After screening and eligibility assessment, 19 studies were included in the final analysis. The results of these studies were heterogenous and partly inconclusive. However, TRAb appears to be the most useful marker in predicting remission. Low baseline TRAb concentrations are associated with a higher probability of remission, while higher values correlate with a more severe clinical course and a greater risk of relapse. The predictive value of FT3 and FT4 as markers is questionable. TSH tends to be the least informative predictor of the outcome. In conclusion, looking at the nature of Graves’ disease, which may be relapsing-remitting, further research in this area is warranted to enhance the quality of life of patients with Graves’ disease.


  • Open Access

    Long-term remission of corticosteroid-resistant Graves’ orbitopathy after therapy with tocilizumab

    by Joanna Rymuza, Aleksander Kuś, Dorota Białas-Niedziela, Monika Turczyńska, Dariusz Kęcik, Tomasz Bednarczuk

    Not required for Clinical Vignettes. Not required for Clinical Vignettes.


  • Open Access

    Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy

    by Joanna Rymuza, Klaudia Gutowska, Dagmara Kurpios-Piec, Marta Struga, Piotr Miśkiewicz

    Background: Treatment with glucocorticoids (GCs) is associated with side effects. In contrast to the well-known negative impact on bone tissue exerted by oral GCs, few data are available regarding intravenous GCs. We investigated the influence of intravenous methylprednisolone (IVMP) on bone turnover markers (BTM): amino-terminal propeptide of type I procollagen (P1NP) and the C-terminal telopeptide of type I collagen (CTX), and on calcium metabolism parameters: 1,25-dihydroxyvitamin D (1,25(OH)2D), 25-hydroxyvitamin D (25(OH)D), calcium (Ca), phosphate (P), and intact parathormone (iPTH). Methods: In a prospective study, 23 consecutive subjects with Graves’ orbitopathy were included and treated with IVMP according to the European Group on Graves’ Orbitopathy recommendations. We evaluated effects on BTM occurring during the first 7 days after 0.5 g IVMP, and after the therapy with 12 IVMP pulses with a cumulative dose of 4.5 g. Results: We observed prompt but transient decrease of P1NP (p < 0.001) and the reduction of CTX (p = 0.02) after the first IVMP pulse. Following the full course of IVMP therapy, both P1NP and CTX were found decreased (p < 0.05 and p < 0.01, respectively). Conclusions: A single pulse of 0.5 g IVMP already decreases bone formation and resorption; however, this change is transient. The full therapy is associated with suppression of bone turnover.


  • Open Access

    Impact of additional intravenous methylprednisolone pulse therapy on the quality of life in patients with dysthyroid optic neuropathy

    by Maryla Pelewicz, Joanna Rymuza, Katarzyna Pelewicz, Piotr Miśkiewicz

    Introduction. Dysthyroid optic neuropathy (DON) is a severe complication of Graves’ orbitopathy (GO). Treatment of DON should involve immediate administration of intravenous methylprednisolone (ivMP) in very high doses. It is recommended to include additional 12 pulses of ivMP according to a weekly schedule as a further step of the treatment process. The purpose of this study was to evaluate the influence of a 12-week ivMP treatment on the quality of life (QoL) in DON patients. Material and Methods. A retrospective study was conducted on 6 patients (the tests involved 8 individual eyes) with DON and treated with ivMP in very high doses, followed by orbital decompression in one patient. All patients were qualified for additional treatment with ivMP in a 12-week protocol and completed the Polish version of the GOQoL questionnaire before and after the therapy. Visual acuity (VA) and diplopia were examined prior to the administration of ivMP pulses for DON, as well as before and after the additional ivMP treatment. Results. A minimal clinically important difference in QoL was observed in four patients at the end of the additional ivMP therapy. A significant increase in VA was observed following additional pulses of ivMP compared to the evaluation at the time of the DON diagnosis (p=0.04). Conclusions. Applying additional 12 pulses of ivMP following DON therapy may impact QoL. Performing QoL assessment throughout the entire therapy in patients with DON is particularly important in the clinical practice. Final evaluation of QoL should be performed after completing the entire therapeutic process, which involves surgical treatment to correct diplopia.